IP Library Granted Patent US 9,956,207
Granted Patent B2
US 9,956,207 · App. 15/207,384 · Granted May 1, 2018

Antifungal compounds

Inventors: Jonathan A. Covel (San Diego, CA); Mitchell Mutz (San Diego, CA); Peter J. Webb (San Diego, CA); Robert Remme Webb, II (San Diego, CA)
Assignee: Amplyx Pharmaceuticals, Inc.
A61K31/436A61K31/01A61K31/131A61K31/407A61K31/4164A61K31/4192A61K31/4196A61K31/425A61K31/437A61K31/497A61K31/5377A61K31/685A61K31/695A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,207
App. No.
15/207,384
Granted
May 1, 2018
Kind
B2
Abstract

The technical field of the invention is in pharmaceutical compounds and methods. In an aspect, the disclosure provides macrolide compounds suitable for use as antifungal agents, as well as methods for their use and compositions containing the same.

Claims (68)

1. An antifungal composition formulated in effective unit dosage and comprising an antifungal compound of formula (I)

wherein:

“a” is a double bond that may be present provided that R 5a is not present;

R 1 is selected from alkyl, alkenyl, or is taken together with R 3 or R 3a to form a cycle;

R 3 and R 3a are independently selected from —H, and —OH, or R 3 and R 3a together form ═X, where X is selected from O, C, and N such that ═X and the carbon atom to which it is attached forms a carbonyl, oxime, substituted oxime, imine, substituted imine, hydrazone, substituted hydrazone, terminal olefin, or substituted olefin functional group, or wherein one of R 3 and R 3a is —H and the other is taken together with R 1 or R 5 or R 5a to form a cycle;

R 5 and R 5a are independently selected from —H, —OH, or —OTBS, or R 5 and R 5a together form ═O, or one of R 5 and R 5a is —H and the other is taken together with R 3 or R 3a to form a cycle;

R 7 is a substituted carboxyl selected from:

and R 7a is —H; and

R9 is selected from —H and —OH,

or a pharmaceutically acceptable salt thereof.

2. The composition of claim 1 , wherein the compound has the structure of formula (IA-c):

3. The composition of claim 1 , wherein the compound has the structure of formula (IF):

4. The composition of claim 1 wherein the compound has a structure selected from the group consisting of:

48

49

54

58

59

60

165

166

191

192

194

195

196

197

198

199

201

214

5. The composition of claim 1 wherein the compound has a structure:

48

6. The composition of claim 1 wherein the compound has a structure:

49

7. The composition of claim 1 wherein the compound has a structure:

54

8. The composition of claim 1 wherein the compound has a structure:

58

9. The composition of claim 1 wherein the compound has a structure:

59

10. The composition of claim 1 wherein the compound has a structure:

60

11. The composition of claim 1 wherein the compound has a structure:

165

12. The composition of claim 1 wherein the compound has a structure:

166

13. The composition of claim 1 wherein the compound has a structure:

191

14. The composition of claim 1 wherein the compound has a structure:

192

15. The composition of claim 1 wherein the compound has a structure:

194

16. The composition of claim 1 wherein the compound has a structure:

195

17. The composition of claim 1 wherein the compound has a structure:

196

18. The composition of claim 1 wherein the compound has a structure:

197

19. The composition of claim 1 wherein the compound has a structure:

198

20. The composition of claim 1 wherein the compound has a structure:

199

21. The composition of claim 1 wherein the compound has a structure:

201

22. The composition of claim 1 wherein the compound has a structure:

214

23. A method for treating a patient suffering from a fungal infection, the method comprising administering to the patient an effective amount of a composition of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2018
From: AMPLYX PHARMACEUTICALS, INC.
To: DUKE UNIVERSITY
Reel/Frame 046441/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2016
From: COVEL, JONATHAN A.; MUTZ, MITCHELL; WEBB, PETER J.; WEBB, ROBERT
To: AMPLYX PHARMACEUTICALS, INC.
Reel/Frame 039308/0940 →
Continuity (3)
Continuation PCTUS2015011247 · Jan 13, 2015
Provisional Application 61926413 · Jan 13, 2014
Related Publication 20160331730A1 · Nov 17, 2016